These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Vasodilation caused by inhibition of calcium ions as a factor of increasing oxygen transport in peripheral vascular diseases]. Pola P; Savi L; Dal Lago A; Zucchiatti V Clin Ter; 1977 Jun; 81(5):417-31. PubMed ID: 884936 [No Abstract] [Full Text] [Related]
6. [Griseofulvin administered for an indeterminate time in the therapy of systemic scleroderma and Raynaud's syndrome]. Giordano M; Capelli L; Ara M; Tirri G Reumatismo; 1971; 23(2):82-92. PubMed ID: 5146109 [No Abstract] [Full Text] [Related]
7. [Symptomatic treatment of Raynaud's phenomenon: reserpine, alpha-methyldopa, griseofulvin, guanethidine]. Zicot M Rev Med Liege; 1980 Oct; 35(19):652-4. PubMed ID: 6161403 [No Abstract] [Full Text] [Related]
8. Griseofulvin in Raynaud's phenomenon. Naidoo P Lancet; 1971 Nov; 2(7733):1090. PubMed ID: 4106930 [No Abstract] [Full Text] [Related]
9. Griseofulvin in Raynaud's disease. Hasker WE Lancet; 1970 Nov; 2(7683):1136. PubMed ID: 4097937 [No Abstract] [Full Text] [Related]
10. Griseofulvin in Raynaud's phenomenon. Allen BR Lancet; 1971 Oct; 2(7729):840-1. PubMed ID: 4106870 [No Abstract] [Full Text] [Related]
13. Skin temperature changes in Raynaud's disease after griseofulvin. Charles CR; Carmick ES Arch Dermatol; 1970 Mar; 101(3):331-6. PubMed ID: 5414890 [No Abstract] [Full Text] [Related]
14. [Study on digital arterial reactivity in a case of Raynaud's disease]. Lipparini R; Semeraro S; Palmieri F Arch Patol Clin Med; 1970 Aug; 46(3):233-50. PubMed ID: 5491567 [No Abstract] [Full Text] [Related]
15. [Raynaud's phenomenon: diagnostic and therapeutic aspects]. Soro P; Occhioni G; Spissu M; Trignano M; Dettori G; Bacciu PP; Biglioli P Chir Ital; 1981 Jun; 33(3):647-60. PubMed ID: 7307205 [TBL] [Abstract][Full Text] [Related]
16. Severe vasospasm following ergot administration. Robb LG West J Med; 1975 Sep; 123(3):231-5. PubMed ID: 1162985 [No Abstract] [Full Text] [Related]
17. [A new peripheral vasodilator prostaglandin E1 in atherosclerosis of lower limb vessels and Raynaud disease]. Kirichenko AA; Novichkova IuN; Zubkova LV; Ter-Gevondian NM; Nenakhova TV Klin Med (Mosk); 1991 Nov; 69(11):40-3. PubMed ID: 1808404 [No Abstract] [Full Text] [Related]
18. [Differential diagnosis of peripheral vasomotor disorders of vibration and nonvibration origin]. Petrenko BE; Vydrin ML Gig Tr Prof Zabol; 1981 Jul; (7):8-11. PubMed ID: 6269964 [No Abstract] [Full Text] [Related]
19. [Preliminary results of a clinical and instrumental study of cerebral and peripheral artery circulation with a new phytotherapeutic agent (Ginko biloba)]. Saponaro A; Gambelli G; Cosentino F Minerva Med; 1971 Dec; 62(97):4838-49. PubMed ID: 5131191 [No Abstract] [Full Text] [Related]
20. The action of tetranicotinoylfructose in peripheral vascular disease. Andrews G; Judge TG; Walkey F Practitioner; 1973 Jul; 211(261):83-5. PubMed ID: 4580277 [No Abstract] [Full Text] [Related] [Next] [New Search]